» Articles » PMID: 9134597

Oxidative Reactions and Schizophrenia: a Review-discussion

Overview
Journal Schizophr Res
Specialty Psychiatry
Date 1997 Apr 11
PMID 9134597
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Now that definitive direct evidence has been obtained that oxidized metabolites of catecholamines-aminochrome (derived from dopamine) and related compounds-occur in the human brain the question this paper explores is what is their function there, if any. They are precursors of neuromelanin and are formed inter alia by co-oxidation by prostaglandin H synthase during the synthesis of prostaglandin H from arachidonic acid. Their further metabolism by NAHPD-cytochrome P450 reductase forms the highly neurotoxic o-semiquinone together with free oxygen radicals. The defenses against these orthoquinones (o-quinones) and o-semiquinones (which include reduction, O-methylation, 5-cysteinylization, glutathione conjugation, conversion to the o-hydroquinone, and neuromelanin formation), and their possible status in schizophrenia, are reviewed. This system is closely linked with glutamate neurotoxicity because glutamate receptors activate PGH synthase and because dopamine toxicity is mediated by these o-quinones acting on NMDA receptors. Interactions between glutamate and dopamine neurotoxicity are explored, including a possible role for the redox properties of catecholamines. The hypothesis is presented that some of the demonstrated cellular damage in the schizophrenic brain may be mediated by catecholamine o-quinones. The significance of the evidence from previous studies carried out 40 years ago, that a closely related catecholamine o-quinone-adrenochrome-has psychotomimetic properties in humans and behavior disrupting properties in animals, is reviewed in the light of these recent findings.

Citing Articles

Proteomic profiling of postmortem prefrontal cortex tissue of suicide completers.

Kim M, Do M, Han D, Son M, Shin D, Yeo I Transl Psychiatry. 2022; 12(1):142.

PMID: 35383147 PMC: 8983647. DOI: 10.1038/s41398-022-01896-z.


Review on NAD(P)H dehydrogenase quinone 1 (NQO1) pathway.

Preethi S, Arthiga K, Patil A, Spandana A, Jain V Mol Biol Rep. 2022; 49(9):8907-8924.

PMID: 35347544 DOI: 10.1007/s11033-022-07369-2.


Functional variant rs2270363 on 16p13.3 confers schizophrenia risk by regulating NMRAL1.

Wang J, Li S, Li X, Liu J, Yang J, Li Y Brain. 2022; 145(7):2569-2585.

PMID: 35094059 PMC: 9612800. DOI: 10.1093/brain/awac020.


GSTM1/GSTT1 double-null genotype increases risk of treatment-resistant schizophrenia: A genetic association study in Brazilian patients.

Pinheiro D, Santos R, de Brito R, Cruz A, Ghedini P, Reis A PLoS One. 2017; 12(8):e0183812.

PMID: 28837637 PMC: 5570380. DOI: 10.1371/journal.pone.0183812.


Neurobiology of schizophrenia onset.

Woo T Curr Top Behav Neurosci. 2013; 16:267-95.

PMID: 23975845 PMC: 4447495. DOI: 10.1007/7854_2013_243.